Delivery Order SPE2DB20D2014-SPE2DB25FC58V
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,819.64 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by July 18, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs. The delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $20,781.90 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of June 26, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,507.05 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and represents a single transaction for pharmaceutical supply to support federal medical needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $5,707.30 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance at the contractor's Conshohocken, Pennsylvania facility. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 28, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical supply vendor, fulfills this...
- The Defense Logistics Agency awarded a delivery order valued at $5,997.38 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 29, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, supplying brand-name and generic...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,727.74 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract, designated as a firm fixed-price delivery order with no set-aside designation, was competitively awarded on August 27, 2025, with an ultimate completion date of August 28, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,701.45 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. This competitively awarded, firm fixed-price contract was issued on September 12, 2025, with an ultimate completion date of September 15, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,238.46 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 14, 2025. This firm fixed price, competitively awarded contract was issued without a set-aside designation and is being fulfilled from the vendor's place of business in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at approximately $78K to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 26, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and...
- The Defense Logistics Agency awarded a $27,880.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 5, 2025. This non-competitive delivery order represents a firm fixed-price purchase under the company's existing contract vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC58VDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,221.17 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance in Conshohocken, Pennsylvania. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 29, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $1 billion and extends through December 2026. This parent contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, holds a significant position within the federal medical procurement landscape. The company has demonstrated its capability to meet competitive federal procurement requirements through numerous delivery orders for diverse pharmaceutical products under the DLA Medical Supply Chain. Repatha (evolocumab) is a PCSK9 inhibitor used to lower cholesterol and reduce cardiovascular risk, representing the type of specialty medication that supports military healthcare system operations. The DLA is planning to establish the Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen to continue serving defense healthcare customers including the Defense Health Agency and U.S. Coast Guard through flexible contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 7/28/25 |